Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Presentations & Publications

Science underlying Rgenix’s pipeline has been published in leading scientific journals and presented at renowned medical conferences.

RGX-104

RGX-202

RGX-019

Discovery Platform